ArticlePloS one2012
Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study.
Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.
- Non-alcoholic fatty liver disease across endocrinopathies: Interaction with sex hormones.Frontiers in endocrinology · 2022Pooled it
- Adult Growth Hormone Deficiency and Metabolic Dysfunction-Associated Steatotic Liver Disease.Current obesity reports · 2026Review
- Non-Invasive Assessment of Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Risk in Acromegaly Indicates Persistence of Cardiac Risks Despite Biochemical Disease Control.Journal of clinical medicine · 2025Article
- Risk factors and prediction model of metabolic disorders in adult patients with pituitary stalk interruption syndrome.Scientific reports · 2025Article
- Liver-specific actions of GH and IGF1 that protect against MASLD.Nature reviews. Endocrinology · 2025 · on this mapReview
- Recent advances in anterior pituitary hormones and metabolic-associated fatty liver disease.Frontiers in endocrinology · 2025Review
- Nonlinear relationship between the triglyceride-glucose index and alanine aminotransferase in children with short stature.Scientific reports · 2024Article
- Effects of Metabolic Dysfunction-Associated Steatotic Liver Disease on Bone Density and Fragility Fractures: Associations and Mechanisms.Journal of obesity & metabolic syndrome · 2024Review
- Relationship between albumin-corrected anion gap and non-alcoholic fatty liver disease varied in different waist circumference groups: a cross-sectional study.European journal of medical research · 2024Article
- Case report: Pediatric hepatopulmonary syndrome despite strict weight control after craniopharyngioma surgery.Frontiers in endocrinology · 2024Article
- Growth hormone/insulin-like growth factor I axis in health and disease states: an update on the role of intra-portal insulin.Frontiers in endocrinology · 2024Review
- Nonalcoholic Fatty Liver Disease, Liver Fibrosis, and Utility of Noninvasive Scores in Patients With Acromegaly.The Journal of clinical endocrinology and metabolism · 2023Article
- Increased GH/IGF-I Axis Activity Relates to Lower Hepatic Lipids and Phosphor Metabolism.The Journal of clinical endocrinology and metabolism · 2023Article
- Important Hormones Regulating Lipid Metabolism.Molecules (Basel, Switzerland) · 2022Review
- Article
- Growth hormone deficiency and NAFLD: An overlooked and underrecognized link.Hepatology communications · 2022Review
- The GH/IGF-1 Axis Is Associated With Intrahepatic Lipid Content and Hepatocellular Damage in Overweight/Obesity.The Journal of clinical endocrinology and metabolism · 2022Article
- Growth Hormone and Insulin-Like Growth Factor 1 Regulation of Nonalcoholic Fatty Liver Disease.The Journal of clinical endocrinology and metabolism · 2022 · on this mapReview
- The pathophysiological mechanism between hypopituitarism and nonalcoholic fatty liver disease.iLIVER · 2022Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Growth hormone (GH) is an important regulator of metabolism and body composition. GH deficiency is associated with increased visceral body fat and other features of the metabolic syndrome. Here we performed a cross-sectional study to explore the association of GH levels with nonalcoholic fatty liver disease (NAFLD), which is considered to be the hepatic manifestation of the metabolic syndrome. A total of 1,667 subjects were diagnosed as NAFLD according the diagnostic criteria, and 5,479 subjects were defined as the controls. The subjects with NAFLD had significantly lower levels of serum GH than the controls. Those with low GH levels had a higher prevalence of NAFLD and the metabolic syndrome. A stepwise logistic regression analysis showed that GH levels were significantly associated with the risk factor for NAFLD (OR = 0.651, 95%CI = 0.574-0.738, P<0.001). Our results showed a significant association between lower serum GH levels and NAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.